entertainment -WSS

entertainment

author：entertainment 2025-09-28 07:21:46 - browse：9972

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Ahead of JPM, here's who's profiting most in health care

WSS

U.K. sequencing study surfaces new findings about tumor DNA

GSK Flovent asthma inhalers replaced by authorized generics

Everything to know for the next Powerball drawing as jackpot hits $1 billion

The biotech scorecard for Q1: 17 stock

U.K. sequencing study surfaces new findings about tumor DNA

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

entertainment

explore

New air purifier tech could be key to improving indoor air quality

Ahead of JPM, here's who's profiting most in health care

Activists slam private health insurers over coverage restrictions

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Medicare details structure of new drug price negotiation program

Woman gored by Bison at Yellowstone

BioMarin wins approval for gene therapy to treat hemophilia A

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Drug repurposing or repositioning? The language matters

Does aspartame cause cancer? What new WHO guidance says

hotspot

Why police arrested suspected Gilgo Beach killer away from his house

New weight loss drugs work. But how can they best be used?

Celiac disease study examines precisely how gluten triggers injury

Why police arrested suspected Gilgo Beach killer away from his house

Care demand spikes challenge UnitedHealth’s provider arm

Argenx drug significantly slows progression of nerve disorder

entertainment

hotspot

hotspot

explore